Global Genomic Response to Neonatal Screening

Global Genomic Response to Neonatal Screening

Copyright: © 2015 |Pages: 30
DOI: 10.4018/978-1-4666-8559-8.ch004


In the age of genomic science, neonatal screening for sickle cell anemia involves critical ethical legal, social, and financial implications. The screening for early identification of children most likely to face the complications associated with sickle cell disease was designed to enable parents utilize the state of the art scientific curative care to enable their children to live economically productive lifestyle. However, screening must not be used for discrimination and refusal to insure patient with sickle cell disease. The availability of bone marrow transplant and gene-therapies are clinical options to assist at-risk patients.
Chapter Preview

Part I: Ethics Of Neonatal Screening For Sickle Cell Anemia

Ethical, Legal, Social, and Financial Implications of Neonatal Screening for Sickle Cell Anemia in Sub-Saharan Africa in the Age of Genomic Science

This project was designed to identify the legal implications associated with the management of sickle cell in newborns and to discuss the socio-cultural implications in the management of sickle cell in newborns. In assessing the ethical components of neonatal screening for sickle cell disease one must consider the implications for screening at-risk subject bearing in mind those there relevant therapeutic interventions for the management of the disease. Besides, conscientious efforts are needed to determine the ethical and the financial implications of treating newborn with sickle cell anemia as a public health priority among physicians, administrators and health educators in Sub-Saharan African (SSA) nations.

Complete Chapter List

Search this Book: